路透社2月28日 - 欧盟人类药品委员会$(CHMP)$ 周五表示，它不会更新对卫材4523.T和百健BIIB.O的阿尔茨海默氏症药物Leqembi的意见，此前该委员会曾于11月建议批准 (link)。
欧盟委员会曾要求CHMP考虑有关Leqembi安全性的信息。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.